CSF3 and acute myeloid leukemia: In the present study, 43% of patients began antifungal therapy during the induction phase, 15% during consolidation and maintenance, 19% during intensification for relapsed patients, and 6% during the fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubicin (FLAG-IDA) protocol for relapsed AML.